Department of Head and Neck Surgery, Miyagi Cancer Center, Natori, Miyagi, Japan.
Department of Plastic and Reconstructive Surgery, Miyagi Cancer Center, Natori, Miyagi, Japan.
Surg Oncol. 2020 Sep;34:197-205. doi: 10.1016/j.suronc.2020.04.025. Epub 2020 May 1.
There are few reports on Enhanced Recovery After Surgery (ERAS)-based perioperative management following head and neck surgery with free tissue transfer reconstruction (HNS-FTTR). Here, we prospectively evaluated our ERAS program involving preoperative glucocorticoid administration in HNS-FTTR.
This prospective study included 60 patients who underwent HNS-FTTR at the Miyagi Cancer Center from June 2017 to December 2018. Their treatment plan included receiving perioperative management in accordance with our head and neck ERAS program. Major outcomes of hospitalization periods, early mobilization, early enteral nutrition, and patient satisfaction were assessed, and blood date and vital signs were compared with control patients who underwent HNS-FTTR from January 2014 to September 2016 at our institution before ERAS was implemented.
The duration of hospital stay and the duration until completion of the discharge criteria was a median of 25 days and 17 days, respectively. Early mobilization was achieved in 86.0% of the patients at postoperative-day (POD)1 and 96.5% at POD2. Enteral nutrition was started in 80.1% at POD1 and 100% at POD2. Postoperative pain was controlled at mean VAS scores of 1.51-3.13. Clavien-Dindo grade II or higher postoperative complications were evident in 27.6% of the patients. The mean QOR40 score was 179.6 preoperatively, 146.1 at POD3, and 167.8 at POD7. Compared with the control group, there were significantly lower C-reactive protein levels, higher albumin levels, a lower body temperature, a lower neutrophil-to-lymphocyte ratio, less body weight fluctuation, and fewer incidences of decreased blood pressure in the ERAS group.
Patients who underwent HNS-FTTR with ERAS-based perioperative management achieved early mobilization, early enteral nutrition, favorable pain control, remarkable recovery of patient satisfaction at POD7, and there was evidence of better hemodynamic stability and less inflammatory response compared with control patients.
关于头颈部游离组织移植重建(HNS-FTTR)术后基于加速康复外科(ERAS)的围手术期管理,相关报道较少。在这里,我们前瞻性地评估了我们的 ERAS 方案,该方案包括术前给予糖皮质激素治疗 HNS-FTTR。
这项前瞻性研究纳入了 2017 年 6 月至 2018 年 12 月在宫城癌症中心接受 HNS-FTTR 的 60 例患者。他们的治疗计划包括按照我们的头颈部 ERAS 方案接受围手术期管理。评估了住院时间、早期活动、早期肠内营养和患者满意度等主要结局,并与在我们机构实施 ERAS 之前(2014 年 1 月至 2016 年 9 月)接受 HNS-FTTR 的对照组患者的血液数据和生命体征进行了比较。
中位住院时间和达到出院标准的时间分别为 25 天和 17 天。术后第 1 天(POD1)有 86.0%的患者能够早期活动,第 2 天(POD2)有 96.5%的患者能够早期活动。第 1 天(POD1)有 80.1%的患者开始肠内营养,第 2 天(POD2)有 100%的患者开始肠内营养。术后疼痛通过平均视觉模拟评分(VAS)控制在 1.51-3.13 分。有 27.6%的患者出现 Clavien-Dindo 分级 II 级或以上的术后并发症。术前 QOR40 评分平均为 179.6,术后第 3 天(POD3)为 146.1,第 7 天(POD7)为 167.8。与对照组相比,ERAS 组的 C 反应蛋白水平较低,白蛋白水平较高,体温较低,中性粒细胞与淋巴细胞比值较低,体重波动较小,血压下降发生率较低。
接受基于 ERAS 的围手术期管理的 HNS-FTTR 患者能够实现早期活动、早期肠内营养、良好的疼痛控制、患者满意度在 POD7 显著恢复,并且与对照组相比,有更好的血流动力学稳定性和更低的炎症反应的证据。